Publications & Presentations

Check out the latest scientific presentations from Kailera Therapeutics.

Effect of Injection Site on the Relative Bioavailability and Safety of Ribupatide, a Novel Dual GLP-1/GIP Receptor Agonist: Phase 1, Randomized, Single-dose, Crossover Trial Results

M. Camargo et al.

European Association for the Study of Diabetes (EASD) 2026

Efficacy and Safety of Ribupatide (HRS9531) in Participants with Obesity and Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Multicenter, Randomized, Double-blind, Phase 2 Trial

J. Hongwei et al.

European Association for the Study of Diabetes (EASD) 2026

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-4729, a Novel GLP-1/GIP/Glucagon Triple-Receptor Agonist: A Randomized, Double-blind, Placebo-controlled Phase 1 Study

European Association for the Study of Diabetes (EASD) 2026

Oral Small Molecule GLP-1RA HRS-7535 as Monotherapy in Chinese Adults with Early Type 2 Diabetes: The OUTSTAND-1 Phase 3 Trial

European Association for the Study of Diabetes (EASD) 2026

Oral HRS-7535 Versus Dapagliflozin in Chinese Adults with Type 2 Diabetes Inadequately Controlled with Metformin: The OUTSTAND-2 Phase 3 Trial

G. Lixin et al.

European Association for the Study of Diabetes (EASD) 2026

HRS-7535, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults with Obesity without Diabetes: a Randomized, Double-blind, Placebo-controlled Phase 2 Trial

Nature Communications, June 2026

A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel GLP-1/GIP Receptor Dual Agonist in Development for People Living with Overweight/Obesity

L. Klickstein et al.

American Diabetes Association (ADA) 2026

Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial

American Diabetes Association (ADA) 2026

Efficacy and Safety of HRS9531, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults Living with Overweight or Obesity Without Diabetes

ObesityWeek® 2025

1 2 3